COMPANY PROFILE

Fesarius Therapeutics

FesariusTherapeutics Inc. is an early stage company that will develop and manufacture engineered skin replacement products

New York City, United StatesFounded 2015Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Fesarius Therapeutics

Fesarius Therapeutics is an emerging bioregenerative technology company specializing in advanced wound care solutions. The company operates in the healthcare and biotechnology markets, focusing on developing, manufacturing, and commercializing innovative products for treating complex wounds. Their core product, the DermiSphere differential density collagen platform, is designed to facilitate advanced dermal regeneration, significantly reducing the need for multiple surgeries. Fesarius Therapeutics primarily serves healthcare providers, including hospitals and clinics, that require effective solutions for severe skin loss and complex wound management. The business model revolves around the commercialization of their proprietary technology, generating revenue through product sales and strategic partnerships. The company has received significant funding, including an $800K SBIR grant and a $1.83 million boost from the NIH, to fast-track their groundbreaking wound care solutions to market.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: New York City, United States
Employees: 18
Open positions: None listed
Dealroom signal: 84.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Fesarius Therapeutics.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jun 2026	$20M	$80M	Johnson & Johnson Innovation · American Society of Plastic Surgeons · Jefferson Life Sciences · New York Ventures	↗
GRANTOther financing	Aug 2023	$800K	—	Undisclosed	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Fesarius Therapeutics website traffic

Latest recorded traffic for Fesarius Therapeutics is 1.5K monthly website visits, down 25% over the last three months. Fesarius Therapeutics's team grew 20% over the past year.

Latest monthly visits1.5K 3-month web change-25% 1-year team growth+20%

Monthly website visitsJan 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SASansanimaHuman cell-based assays replacing animal testing.	Sheffield, United Kingdom	Operational	5	$396K	$1.6M
NKNK:IODeveloping technologies to improve cancer treatment	London, United Kingdom	Operational
PTPhlox TherapeuticsRNA-based gene therapies for genetic heart diseases	Naarden, Netherlands	Operational
EIExciting InstrumentsAccessible single-molecule fluorescence spectroscopy platform for researchers	Sheffield, United Kingdom	Operational
ETEikonizo TherapeuticsDeveloping therapies to improve the treatment of human disease, specifically neurodegenerative diseases	Cambridge, United States	Operational
DODuo OncologyDeveloping a new nanoparticle technology specially tailored to penetrate established tumors	Pittsburgh, United States	Operational
ATAmara TherapeuticsReinventing Women’s Incontinence Care	Galway, Ireland	Operational
GCGORYO ChemicalProvides new fluorescent probes for cellular analysis, assay, and imaging	Sapporo, Japan	Operational